Featured News
Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology
June 16, 2025
Micron Biomedical Names Health Education and Empowerment Advocate, Dr. Jayne Morgan, to Board of Advisors
June 9, 2025
Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines
January 16, 2025
No Needles. Many Applications.
Micron Biomedical develops FDA-regulated drugs that combine vaccines and therapeutics with microscopic structures called “microarrays” that dissolve painlessly and without needles in the upper layers of the skin.
Anytime, Anywhere Access
Micron Biomedical’s clinical-stage pipeline encompasses life-saving vaccines and therapeutics for children and adults that can be painlessly, self-administered in seconds to minutes—at home, in the field, and wherever they are needed—all with the touch of a button.
Breaking infrastructure barriers
Micron is solving some of the most pressing challenges facing conventional vaccine and drug administration by eliminating or greatly reducing the need for cold chain during delivery and/or storage; reducing transportation and storage costs; allowing safe vaccine and drug administration by non-medical personnel; reducing medical waste; and offering needle-free pharmaceuticals to address vaccine hesitancy and improve patient compliance.
“I’m determined to continue to break down the barriers to global vaccine access, and that’s why I’m thrilled to be part of Micron Biomedical.”
Dr. Seth Berkley
Scientific Advisor, Micron Biomedical
“You don’t need a trained healthcare worker to administer the vaccine. You eliminate the fear factor, the risk of blood and body fluids from the needle. For the person administering it, you don’t have medical waste like you do with a syringe and needle.”
